Home/Catalog/FDA Warning Letters & Computerized Systems: From Validation Failures to Inspection-Ready CSV/CSA
← Back to Catalog
Live WebinarNew

FDA Warning Letters & Computerized Systems: From Validation Failures to Inspection-Ready CSV/CSA

Learn what FDA warning letters reveal about software validation, data integrity, audit trails, Part 11, CSV, CSA, change control and inspection readiness.

0(0 reviews)
1.5 hoursMonday, October 5, 2026
Meredith Crabtree

Instructor

Meredith Crabtree

GMP Quality Consultant & Validation Specialist

What You'll Learn

Identify recurring software-validation and computerized-system weaknesses associated with regulatory findings.
Explain how inadequate risk assessment can result in inappropriate validation scope, testing or controls.
Evaluate key computerized-system controls related to data integrity, audit trails, access management and electronic records.
Apply a practical framework for connecting regulatory observations to root cause, impact assessment and remediation.
Differentiate traditional CSV activities from risk-based Computer Software Assurance (CSA) approaches.
Assess how change control, supplier management and cloud/SaaS environments can affect the validated state of computerized systems.
Identify evidence and documentation that can help organizations defend validation and assurance decisions during regulatory inspections.
Recognize additional validation and assurance considerations for AI-enabled computerized systems.

About the event

What can real FDA enforcement findings teach you about the weaknesses in your own computerized systems?

A computerized system may be validated, documented and in daily use, and still leave an organization exposed during a regulatory inspection.

FDA enforcement findings repeatedly highlight weaknesses involving computerized-system controls, audit trails, access controls, data integrity, change management, validation decisions and oversight. At the same time, the regulatory environment is moving toward more risk-based approaches to computer software assurance (CSA), while organizations are increasingly implementing cloud, SaaS, digital quality systems and AI-enabled technologies.

This practical webinar connects these developments. Rather than treating software validation as a collection of documents, the session examines what regulators have actually identified as problematic, why those weaknesses occur, and how organizations can build more defensible validation and assurance strategies.

Participants will learn how to move from:

  1. Regulatory finding
  2. failure pattern
  3. root cause
  4. risk assessment
  5. remediation
  6. inspection-ready evidence

The program combines real-world regulatory lessons with practical CSV/CSA concepts that can be applied to computerized systems used in regulated environments.

The central question: if an FDA investigator challenged your validation decisions tomorrow, could you explain and defend why you did what you did? This webinar is designed to help you answer that question.

WHY YOU SHOULD ATTEND

Regulatory inspections do not focus only on whether a validation document exists. Organizations may also be challenged on whether their systems, controls, data and validation decisions demonstrate effective control. This webinar will help you understand the warning signs.

You will learn how to

  • Identify recurring computerized-system and software-validation weaknesses found in regulatory enforcement.
  • Understand the relationship between validation scope, intended use and risk.
  • Recognize weaknesses involving audit trails, access controls and electronic records.
  • Connect data-integrity concerns to computerized-system controls.
  • Evaluate how change control can affect the validated state of a system.
  • Understand where supplier and cloud/SaaS responsibilities need stronger controls.
  • Apply risk-based thinking when determining validation and assurance activities.
  • Understand the transition from traditional CSV approaches toward CSA.
  • Distinguish meaningful risk-based assurance from simply reducing documentation.
  • Translate a regulatory finding into root cause, impact assessment and remediation activities.
  • Identify the evidence needed to defend validation decisions during an inspection.
  • Recognize additional considerations when computerized systems incorporate AI.

COULD YOUR COMPUTERIZED SYSTEM WITHSTAND THESE QUESTIONS?

  • Why was this system validated to this extent?
  • Where is the documented risk assessment?
  • How did you determine what required testing?
  • Can you demonstrate that critical changes are controlled?
  • Can you prove that electronic records remain trustworthy?
  • How are audit trails configured, reviewed and retained?
  • What happens when your software vendor changes the system?
  • How do you demonstrate that the system remains in a validated state?
  • What evidence would you provide to an investigator?

This webinar examines the types of weaknesses that can make these questions difficult to answer.

KEY TAKEAWAY

The goal is not simply to produce more validation documentation. The goal is to build appropriate, risk-based and defensible assurance that demonstrates control over the computerized system, its data and its intended use.

Participants will leave with a practical framework for asking: What could go wrong? What matters most? What controls are required? What evidence demonstrates that the controls work? How would we defend our decisions during an inspection?

Curriculum

Module 1: What FDA Findings Tell Us About Computerized Systems
10 min
Module 2: The Recurring Failure Patterns
15 min
Module 3: Data Integrity, Audit Trails & Part 11
15 min
Module 4: From CSV to CSA: Risk-Based Assurance
15 min
Module 5: Cloud, SaaS, Vendors & Change Control
10 min
Module 6: From Regulatory Finding to Root Cause & CAPA
10 min
Module 7: AI-Enabled Systems & Emerging Assurance Expectations
5 min
Module 8: Inspection-Readiness Assessment & Key Takeaways
10 min

Requirements

  • Basic familiarity with GxP, quality-system or computerized-system validation concepts is recommended (intermediate level).

Who Should Attend

This webinar is designed for professionals responsible for computerized systems, validation, quality, compliance and data integrity in regulated environments. Primary audience: Computer System Validation (CSV) Professionals, Computer Software Assurance (CSA) Professionals, Validation Managers, Validation Engineers, Quality Assurance Professionals, Quality Systems Professionals, Data Integrity Professionals, GxP IT Professionals, Computerized-System Owners, IT Quality Professionals, Compliance Professionals. Also valuable for: Regulatory Affairs Professionals, Quality Control Professionals, Laboratory Informatics Professionals, LIMS Professionals, Manufacturing Systems Professionals, Digital Transformation Teams, IT Project Managers, Internal Auditors, Supplier/Vendor Quality Professionals, Consultants supporting regulated organizations. Organizations: Pharmaceutical companies, Biotechnology companies, Medical-device manufacturers, Contract manufacturing organizations (CMOs/CDMOs), Contract research organizations (CROs), Laboratory organizations, Life-science technology providers, Organizations implementing cloud or AI-enabled GxP systems.

Areas Covered

What FDA Findings Tell Us About Computerized Systems: what regulators look for when evaluating computerized systems; why "validated" does not automatically mean "well controlled"; common weaknesses identified during inspections; the relationship between software, procedures, people and data; documentation versus effective control
Recurring Software Validation Failure Patterns: inadequate or unclear intended use; poorly defined system boundaries; weak requirements; inadequate risk assessment; inappropriate testing strategies; insufficient traceability; weak change control; inadequate periodic review; poor supplier oversight; failure to maintain the validated state
Data Integrity, Audit Trails & Electronic Records: data integrity fundamentals; ALCOA/ALCOA+ principles; audit-trail configuration and review; user-access controls; privileged/system-administrator access; electronic records and signatures; data review and approval; backup and restoration considerations; handling incomplete, altered or deleted records
CSV to CSA: traditional Computer System Validation and Computer Software Assurance; risk-based assurance and critical thinking; intended use; patient safety, product quality and data integrity; determining appropriate testing effort; evidence-based validation decisions; avoiding both over-validation and under-control; building a defensible assurance strategy
Cloud, SaaS & Supplier Controls: shared responsibility; vendor qualification; supplier documentation; cloud configuration; system updates and releases; change notifications; vendor testing evidence; service-level responsibilities; maintaining control after implementation
From Finding to Root Cause and CAPA: understanding the actual failure; determining scope; assessing data and product impact; retrospective review; root-cause analysis; corrective and preventive action; effectiveness checks; demonstrating sustained remediation
AI-Enabled Computerized Systems: AI use within regulated workflows; defining intended use; risk-based assessment; verification of AI outputs; human oversight; data quality; performance monitoring; change management; documentation and traceability
Inspection Readiness: what evidence should be readily available; how to defend validation decisions; how to identify weak areas before inspection; building an inspection-readiness checklist; turning regulatory lessons into preventive action

Meet Your Instructor

Meredith Crabtree

Meredith Crabtree

GMP Quality Consultant & Validation Specialist

Meredith Crabtree has over 30 years' experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting and specializes in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.

30+ Years GMP ExperienceIQ/OQ/PQ SpecialistConsent Decree SupportMulti-Industry QA Expert
Quantity
1

Single: 1 Attendee

$240.00
Buy Now
Secure payment via Stripe
Certificate of completion

Event Details

Format

Live Webinar

Duration

1.5 hours

Certificate

Included

Date

Monday, October 5, 2026

Topics

FDACSVCSAData IntegrityPart 11GxPInspection ReadinessSoftware Validation

Related Events

Digital Quality Metrics and AI/ML Analytics: Building a Continuous-Improvement Framework that Aligns with Regulatory Expectations
Live WebinarNew
Regulatory & ComplianceCertificate

Digital Quality Metrics and AI/ML Analytics: Building a Continuous-Improvement Framework that Aligns with Regulatory Expectations

Learn how AI/ML and real-time digital quality metrics build a continuous-improvement framework aligned with FDA regulatory expectations, 21 CFR Part 11, and GAMP®5.

Carolyn TroianoCarolyn Troiano
1.5 hoursJun 18, 2026
4.9
from$145.00
View Details
AI in GMP: What the FDA Is Already Expecting - Before You Ask
Live WebinarNew-24%
Regulatory & ComplianceCertificate

AI in GMP: What the FDA Is Already Expecting - Before You Ask

FDA already expects GMP compliance for AI systems. Learn how existing validation, data integrity, and oversight rules apply—before regulators come calling.

Dr. Ginette CollazoDr. Ginette Collazo
1.5 hoursJun 30, 2026
4.8
from$190.00$250.00
View Details
HPLC Analytical Method Development and Validation
Live WebinarNew
Regulatory & ComplianceCertificate

HPLC Analytical Method Development and Validation

Master HPLC instrument and method validation to meet US EPA and FDA requirements for pharmaceutical analysis.

Dr. John C. FetzerDr. John C. Fetzer
1 hourJun 17, 2026
4.8
from$145.00
View Details